These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19451501)

  • 1. Primary cutaneous melanomas seen as inflamed pigmented lesions in patients undergoing adjuvant interferon treatment: a possible diagnostic clue for physicians.
    Hu S; Kim CC; Jessup C; Phung TL; Curiel-Lewandrowski C
    Arch Dermatol; 2009 May; 145(5):565-8. PubMed ID: 19451501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas.
    Haenssle HA; Mograby N; Ngassa A; Buhl T; Emmert S; Schön MP; Rosenberger A; Bertsch HP
    JAMA Dermatol; 2016 Mar; 152(3):291-8. PubMed ID: 26536613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.
    Dubois RW; Swetter SM; Atkins M; McMasters K; Halbert R; Miller SJ; Shiell R; Kirkwood J
    Arch Dermatol; 2001 Sep; 137(9):1217-24. PubMed ID: 11559220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
    Kimyai-Asadi A; Usman A
    J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of primary and regional melanoma].
    Dreno B
    Rev Prat; 2004 Jun; 54(11):1203-9. PubMed ID: 15496027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current therapy of carcinoma of the skin].
    Dummer R; Goldinger SM; Sailer E; French LE
    Ther Umsch; 2010 Sep; 67(9):447-52. PubMed ID: 20806173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study.
    Cameron DA; Cornbleet MC; Mackie RM; Hunter JA; Gore M; Hancock B; Smyth JF;
    Br J Cancer; 2001 May; 84(9):1146-9. PubMed ID: 11379605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma.
    Fisher NM; Schaffer JV; Berwick M; Bolognia JL
    J Am Acad Dermatol; 2005 Sep; 53(3):393-406. PubMed ID: 16112344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of cutaneous melanoma.
    Tsao H; Atkins MB; Sober AJ
    N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
    [No Abstract]   [Full Text] [Related]  

  • 13. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanomas reveal their nakedness: uncovered by interferon alfa.
    Arbiser JL; Bonner MY
    Arch Dermatol; 2009 May; 145(5):587-8. PubMed ID: 19451506
    [No Abstract]   [Full Text] [Related]  

  • 16. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of dermoscopy in the recognition of melanoma.
    Skvara H; Teban L; Fiebiger M; Binder M; Kittler H
    Arch Dermatol; 2005 Feb; 141(2):155-60. PubMed ID: 15724011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
    McMasters KM; Swetter SM
    J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas.
    Thomé SD; Loprinzi CL; Heldebrant MP
    Mayo Clin Proc; 2002 Sep; 77(9):913-7. PubMed ID: 12233924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.